Get the Stockscreener App
2.82
3.09%
-0.09
After Hours:
2.83
0.01
+0.35%
Perspective Therapeutics Inc stock is traded at $2.82, with a volume of 811.55K.
It is down -3.09% in the last 24 hours and down -7.24% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$2.91
Open:
$2.95
24h Volume:
811.55K
Relative Volume:
0.46
Market Cap:
$321.61M
Revenue:
$618.00K
Net Income/Loss:
$-111.65M
P/E Ratio:
-2.0201
EPS:
-1.396
Net Cash Flow:
$-107.53M
1W Performance:
-3.42%
1M Performance:
-7.24%
6M Performance:
+4.44%
1Y Performance:
-30.54%
1-Day Range:
$2.82
$3.02
1-Week Range:
$2.82
$3.03
52-Week Range:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.82 | 331.87M | 618.00K | -111.65M | -107.53M | -1.396 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Piper Sandler | Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
CATX|Perspective Therapeutics Inc|Price:2.820|Chg%:-0.090 - TradingKey
Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Perspective Therapeutics Market Sentiment - Benzinga España
CATX|Perspective Therapeutics Inc|Price:2.910|Chg%:-0.045 - TradingKey
Perspective Therapeutics Inc (CATX) Cash Flow - TradingKey
Perspective Therapeutics Inc (CATX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Perspective Therapeutics Inc - TradingKey
Perspective Therapeutics, Inc. Revenue Breakdown – TRADEGATE:AAJ0 - TradingView
BTIG reiterates Perspective Therapeutics stock rating on manufacturing edge - Investing.com
Perspective Therapeutics Inc (CATX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Perspective Therapeutics Dips 0.67% as Stock Hovers Near Support ZoneFair Value Gap - dars.gov.et
Perspective Therapeutics (CATX) gains 5.3% beneficial holder led by Millennium - Stock Titan
Perspective Therapeutics (CATX) Bank of America Global Healthcare Conference 2026 summary - Quartr
Perspective Therapeutics (CATX) RBC Capital Markets Global Healthcare Conference 2026 summary - Quartr
Perspective Therapeutics (CATX) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Perspective Therapeutics to present updated can... - Pluang
Perspective Therapeutics Announces ESMO 2026 Presentation of Updated [212Pb]VMT-α-NET Data in Advanced Neuroendocrine Tumors - Quiver Quantitative
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026 - marketscreener.com
Perspective's cancer-treatment data gets ESMO oral presentation Oct. 23 - Stock Titan
Is Perspective Therapeutics, Inc. (CATX) stock outpacing its medical peers this year? - MSN
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Perspective Therapeutics (CATX) Slides Over 5% as Support Levels Come into FocusOutside Reversal - dars.gov.et
CATX: Key Management Meeting Insights from BTIG Analyst - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Perspective Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role - marketscreener.com
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor - The Manila Times
Perspective Therapeutics names Paul Lyne as Chi... - Pluang
Perspective Therapeutics (CATX) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr
Perspective Therapeutics (CATX) Q4 2025 earnings summary - Quartr
Perspective Therapeutics (CATX) Proxy filing Summary - Quartr
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Tenaya Therapeutics (TNYA) - The Globe and Mail
Perspective Therapeutics (CATX) UBS Global Healthcare Conference Summary - Quartr
CATX Q1 2026 Earnings: Narrower Loss Beats Expectations as Pipeline Progress ContinuesRevenue Growth Report - dars.gov.et
Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Perspective Therapeutics Expands Radiopharmaceutical Pipeline to Target Brain Tumors - sekbernews.id
Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials - Yahoo Finance
Perspective Therapeutics (CATX) Surges 4.9% as Bullish Momentum Tests Key ResistanceBPI Bull Confirmed - DonanımHaber
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Treatment and Melanoma - Minichart
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline - TipRanks
Perspective Therapeutics (CATX) updates radiopharmaceutical oncology pipeline presentation - Stock Titan
Millennium reports 4.89M shares (4.3%) in Perspective Therapeutics | CATX SEC FilingForm SCHEDULE 13G - Stock Titan
CATX: Analyst Engages with Management in Virtual Discussion - GuruFocus
Perspective Therapeutics, Inc. Actuals & Estimates (AMEX:CATX) - TradingView
Perspective Therapeutics, Inc. Actuals & Estimates (TRADEGATE:AAJ0) - TradingView
Enterprise value to revenue forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Price to earnings forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
CATX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Perspective Therapeutics Inc (CATX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Perspective Therapeutics Inc (CATX) Institutional Confidence - TradingKey
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Cap:
|
Volume (24h):